This article summarizes available data for the use of CYP3A4 inhibitors with midostaurin for acute myeloid leukemia.
Danielle Schlafer, PharmD, BCOP
Advertisement
Articles by Danielle Schlafer, PharmD, BCOP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer
2
FDA Approves Sonrotoclax in Relapsed/Refractory Mantle Cell Lymphoma
3
FDA OKs Oral Decitabine/Cedazuridine Plus Venetoclax in Newly Diagnosed AML
4
Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC
5